Cantor Fitzgerald analyst Irina Rivkind Koffler reiterated a Buy rating and boosted her price target on Synergy Pharmaceuticals (NASDAQ: SGYP) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Rumors

Synergy (SGYP) PT Lifted to $19 at Canaccord Genuity; 'This Thang Don't Stank'June 18, 2015 9:50 AM Mizuho Maintains Bullish View on Ironwood (IRWD) Linzess Amid Synergy (SGYP) SuccessJune 17, 2015 8:30 AM Synergy Pharma's (SGYP) Phase 3 Trial of Plecanatide in Patients with CIC Mets Primary EndpointJune 17, 2015 6:37 AM Synergy Pharmaceuticals Announces Positive Results in the First Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC)June 17, 2015 6:00 AM